Oppenheimer Holdings, Inc. set a $21.00 price target on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a report published on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ FY2021 earnings at $0.98 EPS.

VNDA has been the topic of several other research reports. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a hold rating to a strong sell rating in a research note on Tuesday, July 18th. Piper Jaffray Companies reissued an overweight rating and issued a $23.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Jefferies Group LLC reissued a buy rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, May 25th. TheStreet raised shares of Vanda Pharmaceuticals from a d+ rating to a c- rating in a research note on Friday, May 12th. Finally, HC Wainwright initiated coverage on shares of Vanda Pharmaceuticals in a research note on Friday, May 26th. They issued a buy rating and a $18.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $21.22.

Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 16.00 on Thursday. The stock has a 50 day moving average price of $15.89 and a 200-day moving average price of $14.60. Vanda Pharmaceuticals has a 1-year low of $11.58 and a 1-year high of $18.00. The firm’s market cap is $715.49 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.88%. The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 earnings per share. Equities research analysts forecast that Vanda Pharmaceuticals will post ($0.61) EPS for the current year.

WARNING: “Oppenheimer Holdings, Inc. Analysts Give Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) a $21.00 Price Target” was posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/oppenheimer-holdings-inc-analysts-give-vanda-pharmaceuticals-inc-nasdaqvnda-a-21-00-price-target.html.

Several hedge funds have recently modified their holdings of VNDA. Cheyne Capital Management UK LLP boosted its stake in shares of Vanda Pharmaceuticals by 42.3% in the first quarter. Cheyne Capital Management UK LLP now owns 74,000 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 22,000 shares during the period. Weiss Multi Strategy Advisers LLC boosted its stake in shares of Vanda Pharmaceuticals by 20.0% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 10,000 shares during the period. Prudential Financial Inc. boosted its stake in shares of Vanda Pharmaceuticals by 0.8% in the first quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock worth $8,600,000 after buying an additional 4,700 shares during the period. American International Group Inc. boosted its stake in shares of Vanda Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after buying an additional 1,491 shares during the period. Finally, FMR LLC boosted its stake in shares of Vanda Pharmaceuticals by 60.7% in the first quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after buying an additional 604,900 shares during the period. 91.42% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.